Global Mycoplasma Testing Market is slated to see a lucrative growth rate of 11% by 2027

Mycoplasmas are the smallest known free-living microorganisms and are frequent contaminants of mammalian cell cultures. For the safety and purity of vaccines and other biological cell-derived products, it is crucial that the cell substrates and unprocessed bulk materials are free of adventitious agents, including mycoplasma. 

In many cases, mycoplasmas vary from other forms of bacteria, making them difficult to culture and identify. Testing is done to detect mycoplasma like Mycoplasma hominis, Mycoplasma genitalium, Mycoplasma pneumoniae, and Ureaplasma urealyticum which can cause nongonococcal urethritis (NGU), prostate inflammation (prostatitis), vaginal discharge, and pelvic inflammatory disease (PID) in both men and women.

Rising Concerns of Cell Culture Contamination to Trigger the Growth of the Global Mycoplasma Testing Market

Mycoplasmas randomly contaminate the fluids used in the bioprocessing and cell culture. It is commonly known that primary cell cultures have a minimum contamination rate of 1% and continuous cell cultures have a contamination rate of between 15% and 35% due to mycoplasma. Ineffective culturing methods or old laboratory apparatus can result in mycoplasma contamination. Reusing pipet tips is an example of poor culture method which might spread the contaminant by transferring mycoplasma-infected media into sterile media. Further, a faulty laminar flow might spread mycoplasma-carrying dust and aerosols throughout a biosafety cabinet, contaminating all the medium and cells within. 

The mycoplasmas mainly enter the cell culture through many difficulties to trace sources. These include healthcare workers in the lab, serum, material used in cell culture, water baths, incubators. Among the mentioned sources, contamination by patients accounts for the highest share. The contaminants can be transmitted through dirty clothes, lab gear, people speaking extremely close to a laminar airflow, the scalp, sneezing, coughing, etc. Also, wherever the cell cultures are kept, a steady inflow of people will raise the possibility of contamination. Out of over 190 total species of mycoplasma, only 20 distinct mycoplasma species of human, bovine, and porcine origin have been found in cell culture. Eight of the species account for nearly 95% of all mycoplasma contamination in cell culture. These includes M. arginini (bovine), M. fermentans (human), M. hominis (human), M. hyorhinis (porcine), M. orale (human), M. pirum (human), M. salivarium (human), and Acholeplasma laidlawii (bovine).

Regular testing is the best protection method against mycoplasma contamination which can identify the contaminated cultures and reagents. In the case of batch adulteration or a product recall, contamination of cell substrates used in the development of biopharmaceuticals constitutes a major economic risk for manufacturers as well as a safety concern for patients. Regular mycoplasma testing is essential to be performed during the product manufacturing and development phase to prevent these risks.

Aggressive Strategies Followed by the Established Market Players and Laboratories in the Global Mycoplasma Testing Market

Rapid innovations and developments in the mycoplasma detection have enabled the leading market players to develop an innovative, advanced, quick, and an easy-to-use tests. Such innovations tend to offer a comprehensive edge to all the manufacturers and thus, market players are emphasizing on growing their investments for new product development and enhancing their regional reach to boost their current position in the global mycoplasma testing market. 

Inspite of the emerging challenges in the global mycoplasma testing market such as long turnaround time, quality control issues, lengthy analytical and lead time, etc. the global mycoplasma testing market has a great potential to grow at a healthy rate and is slated to witness a consistent momentum in the coming years due to a major focus on technological advancements, wider and global acceptance in biopharmaceutical manufacturers, and rapid developments of rapid mycoplasma testing by leading market players in the mycoplasma testing market. 

Competitive Landscape Analysis: Mycoplasma Testing Market

The global mycoplasma testing market is marked by the presence of some of the leading market players such as Thermo Fisher Scientific; Charles River Laboratories International; Merck KGaA; Lonza Group; PromoCell GmbH; American Type Culture Collection.

Get Detailed Insights on Mycoplasma Testing Market with a FREE Sample Report @ https://meditechinsights.com/mycoplasma-testing-market/


Comments

Post a Comment

Popular posts from this blog

Global HPV Testing and PAP Test Market is slated to grow at a lucrative CAGR of 12 to 15 % by 2027 – Growing Revolution for the Prevention of Cervical Cancer

Cervical cancer is a malignant tumor which starts in the cells of the cervix, the lowermost part of the uterus. Cervical cancer begins when the cells on its surface transforms into precancerous cells. If not destroyed, these abnormal cells may turn into harmful cancer cells and spread in the cervix and surrounding areas. Cervical cancer screening involves HPV and PAP tests , which can identify HPV infection or pre-cancerous lesions at an early stage and if correct treatment is offered at the right time then the cancer can be prevented. Impact of  Covid-19 on  the Global HPV Testing and PAP Test Market Covid-19 pandemic had impacted the healthcare market in many ways. During Covid pandemic, due to strict social-distancing norms in hospitals, there was a delay in many diagnostic examinations and procedures. The delay in the cancer screening services due to the lack of skilled healthcare staff and disruption in the supply chain of testing kits across the world had led to a severe impact o
Read more

Global Ambulatory Surgical Center (ASC) Software Market is Poised to Grow at a CAGR of 10% by 2027

Ambulatory Surgical Care is a medical care offered in the outpatient setting and does not need any hospital admission. Ambulatory Surgical Center or ASCs—are health care facilities focused on offering same-day surgical care, including diagnostic and preventive procedures. ASCs have transformed the outpatient experience by offering a convenient alternative to hospital-based outpatient procedures. Common procedures performed in ASCs are cataract surgery, gallbladder removal, tonsillectomy, endoscopy, colonoscopy, arthroscopic or orthopedic procedures, and cardiac procedures. Owing to their various cost benefits and convenience, the volume of procedures performed at ASCs is rising and ASC software is likely to play a major role in these settings by easing the day to day operations by preparing staff and patients for pre-op and post-op tasks. Rising Investments in Ambulatory Surgical Center  from Healthcare Companies Shows a Huge Growth Potential for Ambulatory Surgical Center Software Ma
Read more

Global Genomics Market Report Reveals Rapid Growth & Transformative Trends in the Genomic Industry by 2027

In the ever-evolving landscape of healthcare, genomics is making headlines for its groundbreaking contributions to personalized medicine, disease understanding, and advancements in pharmaceutical research. The Global Genomics Market Report for 2023 highlights the impressive growth and transformative trends within the genomics industry, shedding light on the exciting potential of genomics in shaping the future of healthcare. I. The Genomics Market Landscape The report's comprehensive analysis of the global genomics market reveals a dynamic and rapidly expanding landscape. With a CAGR of over [X]% during the forecast period, the industry is experiencing unprecedented growth. Key factors driving this growth include increased adoption of genomics in clinical diagnostics, expanding genomics research initiatives, and the development of advanced sequencing technologies. II. Personalized Medicine Revolution One of the most exciting trends highlighted in the report is the integration of ge
Read more